Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot. But as scrutiny builds ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna announced that in the Phase 1/2 study, mRNA-1083 appeared to achieve antibody titers similar to or greater than both the licensed flu shot and the updated Covid-19 vaccine.

Moderna presented early data from clinical trials of its mRNA-based flu vaccine. The shots didn’t generate more antibodies than shots already on the market.

Moderna started the first trial for its mRNA-based flu vaccine. The success of the mRNA COVID-19 vaccines accelerated work on other shots using the same approach.

Moderna and Pfizer have plans to combine Covid-19 mRNA shots with those for flu and RSV in the years ahead if studies show that they're safe and effective.

(CNN) — Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in ...